Acrivastine
Systematic (IUPAC) name | |
---|---|
(E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl- prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a682619 |
Pregnancy category |
|
Routes of administration | oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Biological half-life | 1.5 hours |
Excretion | Renal |
Identifiers | |
CAS Number | 87848-99-5 |
ATC code | R06AX18 (WHO) |
PubChem | CID 5284514 |
ChemSpider | 4447574 |
UNII | A20F9XAI7W |
KEGG | D02760 |
ChEBI | CHEBI:83168 |
ChEMBL | CHEMBL1224 |
Chemical data | |
Formula | C22H24N2O2 |
Molar mass | 348.438 g/mol |
| |
| |
(what is this?) (verify) |
Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking histamine H1 receptors.
This non-sedating antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories. It should not be confused with Benadryl Once a Day which has cetirizine as the active ingredient and is also sold by McNeil in the UK. It is available as an over-the-counter medicine in the UK, and is available with or without pseudoephedrine under the Benadryl brand.
In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D also contains the decongestant pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]
Comparisons with other popular antihistamines
Unlike cetirizine or loratadine, for which the standard dose is one tablet per day, a single acrivastine tablet may be taken up to three times a day.[2] It is not to be taken by over 65s, pregnant women, or people with compromised liver or kidney function.
References
- ↑ SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
- ↑ "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Retrieved 4 July 2014.
|